Introduction
Gene therapy has attracted much attention as an innovative mode of treatment for ovarian cancer and is currently under intensive clinical investigation for a variety of transgenes. In ongoing studies, the replicationdeficient adenovirus type 5 is mostly favored over alternatively available viral vector systems for gene delivery into tumor cells. [1] [2] [3] [4] Due to its ability to transfer genes into non-dividing cells this highly infectious adenoviral system was found to be also suitable for treatment of malignancies characterized by a low mitotic index.
In addition to conventional gene therapeutic approaches, adenovirus-derived oncolytic viruses constitute a rapidly evolving new platform for cancer treatment. The best characterized representative of these replication-selective adenoviral agents is dl1520 (ONYX-015), which lacks the E1B-55K gene. ONYX-015 revealed promising preclinical and clinical results in the treatment of various malignancies, including ovarian cancer with a non-functional p53 or p14 ARF pathway. [5] [6] [7] More recently, an E1A mutant adenovirus, d/922-947, with a still higher oncolytic potency was identified. This engineered virus is unable to inactivate the family of retinoblastoma (Rb) proteins and thus lyses only cells with abnormalities in the Rb pathway which occur in a broad range of cancers. 8 A pronounced bystander effect caused by a self-perpetuating infection of adjacent cells after cytolysis of primary targeted cells is considered a further advantage of these replication-selective oncolytic viruses.
For both modalities, conventional gene therapy and oncolytic treatment, virus entry into target cells represents the rate-limiting step and ultimately determines the efficacy of these therapeutic approaches. Initial binding of adenovirus to cell surface has recently been found to be mediated via a specific 46 kDa coxsackie-adenovirus receptor (CAR). 9 The head domain of the adenoviral fiber protein, also called fiber-knob, is responsible for attachment of the virus to this cell surface receptor. After the initial binding step, the viral particle achieves endocytotic internalization via interaction with integrins of the ␣v␤3 and ␣v␤5 classes. 10 It has been assumed that these molecules crucially involved in virus entry into target cells are ubiquitously expressed. Several clinical gene therapy trials, however, have noted relative resistance of target tissues to adenoviral infection. 11 Deficiency of the primary adenovirus receptor CAR and/or integrin dysregulation in tumor cells has been understood to be the biological basis for this phenomenon. [12] [13] [14] Ongoing clinical gene therapeutic and virus-mediated oncolytic trials, however, have not taken into account the degree of expression of these cell surface molecules involved in virus uptake, which may be a reliable predictor of the efficiency of adenovirus-based therapies.
Although tissue distribution of the various classes of integrins has been investigated in different tumor entities 15, 16 and a considerable number of studies has addressed the expression of CAR in established malignant cell lines, to our knowledge only few data are available on the exact expression and distribution of CAR in malignant human tissues, including ovarian cancer. 17 Therefore, the present investigation determines the expression of CAR by means of immunohistochemistry in fresh-frozen ovarian cancer tissue using the highly specific monoclonal antibody RmcB. 18 In addition, the expression of integrin classes ␣v␤3 and ␣v␤5, both of which are involved in the CAR-dependent internalization of adenoviruses, was immunohistochemically assessed. For the three molecules mentioned, special interest was focused on the distributional pattern and heterogeneity of immunostaining within each of the investigated tumor specimens.
Results

Specimens
Twenty-six (70%) of the 37 ovarian cancer samples were obtained from patients with advanced disease (FIGO stage III and IV). The majority of the ovarian cancers included were either of serous (43%) or mucinous (38%) histological subtype. FIGO stage and histopathologic characteristics of the tumor samples are detailed in Table 1 .
Expression of the coxsackie-adenovirus receptor (CAR)
In 36 out of 37 (97%) investigated ovarian carcinoma specimens CAR expression was demonstrable by immunohistochemistry. Semiquantitative assessment of immunostaining gave HScores ranging between 0 and 255 with a median value of 140 (Q 1 : 80 and Q 3 : 160). The only specimen found to be negative for CAR was an undifferentiated carcinoma. Among the various histological tumor types, no consistent differences in the degree of CAR expression could be determined ( Table 2) . As depicted in Figure 1 CAR immunostaining was strictly confined to carcinoma cells, and in none of the examined sections was a specific RmcB reactivity demonstrable either in the stromal component of the tumor or in endothelial cells of tumor blood vessels. In 31 of the 36 positive samples (86%) immunostaining was predominantly observed on the cell membrane (Figure 2a) , and in five cases (14%) cytoplasmic staining was found to be more intense than that of the cell membrane. While in solid parts of the carcinomas membrane staining was equally distributed over the cell surface, in cells lining cystic areas the apical membranes regularly exhibited the most prominent immunoreactivity. No consistent relationship between cellular antigen distribution and pathohistological tumor type or grade was shown. With regard to intratumoral CAR expression, distributional heterogeneity became apparent in all the sections examined. In 22 carcinomas (61%), a focal pattern of heterogeneity, exhibiting CAR-positive regions adjacent to completely negative areas, was demonstrated ( Figure 2b ). It is of note that five of the six (84%) CAR-expressing undifferentiated carcinomas showed a marked degree of focal immunostaining (Figure 2c and d). The remaining 14 tumors (39%) revealed a randomly scattered distribution of CARpositive and -negative cells.
Expression of ␣v␤3 and ␣v␤5 class integrins
In the sections investigated, integrins of the ␣v␤3 and ␣v␤5 classes were immunohistochemically detectable in 62% (23/37) and 65% (24/37) of carcinomas, respectively. Semiquantitative evaluations revealed maximal HScores of 150 for ␣v␤3 integrins and 140 for ␣v␤5 integrins. The respective median HScore values were 20 (Q 1 : 0 and Q 3 : 40) and 40 (Q 1 : 0 and Q 3 : 90). Expression of both integrin classes was found to be independent of the histopathological grading of the carcinomas. Although no differences in the ␣v␤3 and ␣v␤5 immunostaining of serous and mucinous tumors was evident, it is worth noting that ␣v␤3 class integrins were completely absent in all investigated carcinomas classified as undifferentiated and that ␣v␤5 integrin class was demonstrated in only two of the seven cancers of that histological subtype (Table 2) . Nonetheless, the HScores obtained for ␣v␤3 and ␣v␤5 classes of integrins showed a high statistical association (r s : 0.464; P Ͻ 0.005).
Immunostaining for ␣v␤3 and ␣v␤5 integrins was generally confined to the cell membrane of tumor cells. In cystic areas of the carcinomas, intense staining frequently occurred either on the basal or apical cell surface ( Figure  3a ). The pattern of membrane staining, however, was not found to be specific for a particular pathohistological tumor type. For both ␣v␤3 and ␣v␤5 classes of integrins a marked intratumoral heterogeneity of either focal (Figure 3b and c) or scattered ( Figure 3d ) pattern was noticed. In 48% (11/23) and 58% (14/24) of the samples positive for ␣v␤3 and ␣v␤5, respectively, a focal pattern of distributional heterogeneity was found. Whereas the stromal component of the carcinomas completely lacked ␣v␤3 integrin expression, it showed moderate to strong immunoreactivity for the ␣v␤5 integrin class in 11 of the 24 positive (46%) and in five of the 13 negative (38%) samples. Furthermore, endothelial cells of tumor blood vessels generally exhibited strong immunostaining for both ␣v␤3 and ␣v␤5 integrins, regardless of whether malignant cells were positive or negative.
Comparison of CAR expression with that of ␣v␤3 and ␣v␤5 class integrins
When, for each individual tumor the three investigated cell surface molecules were considered together and special attention was attributed to the pattern of intratumoral antigen distribution, only 12 (32%) of the 37 specimens were found to meet the prerequisites for an optimal adenovirus-directed cell targeting. Of note is that seven of these 12 tumors were grade 1 carcinomas. Three additional specimens (8%) showing a low grade of focal heterogeneity in terms of small negative cell clusters interspersing an otherwise positive tumor, were classified as moderately eligible for an adenovirus-based therapy. The remaining 22 samples (60%), however, either because they completely lacked one or the other investigated surGene Therapy face antigen and/or because they exhibited a pronounced focal pattern of antigen expression could not be regarded as suitable candidates for adenovirus-based therapeutic approaches (Table 3) .
Discussion
Gene therapy is one of the most promising new therapeutic options in the treatment of cancer. Besides the selection of key genes as ideal candidates for gene transfer technologies, the choice of adequate vector systems with maximal transduction potency is a crucial factor in the efficacy of this novel approach. Most gene therapy protocols favor adenoviral vectors over alternatively available vector systems. Even though other molecules, such as heparan sulfate glycosaminoglycans, HLA class I or free cholesterol, have been reported to favor or participate in virus uptake, [19] [20] [21] the expression of CAR and integrins of the ␣v␤3 and ␣v␤5 classes on the surface of target cells has been understood to be a prerequisite for adenoviral cell entry and is thus decisive for the efficiency of gene therapy. 9, 10 This is also true for adenovirus-derived oncolytic viruses, such as ONYX-015 and d/922-947, which use essentially the same means of cell entry. Recently, relative resistance of malignant cells to adenovirus-based transfection has been connected to a dysregulation in CAR and/or integrin expression on target cell membranes. [12] [13] [14] In earlier investigations we showed marked differences in CAR expression at the mRNA level in primary cultured ovarian cancer cells. 22 Similarly, in other cancer types such as melanoma, glioma, bladder and prostate cancer, variable expression of the CAR gene has also been documented. 13, 14, 23, 24 To date, there are no indications that DNA mutations or rearrangements of the CAR gene account for the lost or reduced CAR expression in tumor cells. 13 Epigenetic transcriptional regulation appears to play a pivotal role in modulating CAR expression.
In melanoma and glioma cell cultures, CAR and not ␣v␤3-or ␣v␤5-type integrins, was found to be the most reliable predictor of the transduction rate of adenovirus type-5.
24,25 However, Bruning et al 26 recently reported that the loss of ␣v␤3 integrins and especially the ␤3 subunit can decisively compromise adenoviral transduction efficiency in established ovarian cancer cell lines. On the other hand, Li's group 27 showed that in human embryonic kidney cell line HEK293 the lack of ␣v␤3 and ␣v␤5 integrins can be bypassed via ␣v␤1 integrins in adenovirus cell entry. However, the integrin repertoire of this cell line has not been clearly established. Several reports indicate that HEK293 cells do not express ␣v␤3 and ␣v␤5 integrins, [27] [28] [29] while another recent report denotes that they do. 30 Taken together, these data reveal that the mechanism of adenoviral internalization is not yet fully understood.
Ovarian cancer is considered an attractive tumor entity for virus-based gene therapy since it usually remains confined to the abdominal cavity throughout its course and thus allows vector delivery via intraperitoneal route. This locoregional administration of drugs proved to be feasible and effective [31] [32] [33] and in gene therapy offers the advantage to achieve a high virus load in the close tumor environment with reasonable side-effects due to the delayed systemic vector exposure. These facts together with the high rate of more than 55% dysfunctions in the tumor suppressor p53 in advanced ovarian cancer 34 prompted the initiation of a large phase II/III randomized international gene therapy study in patients with p53-mutated primary ovarian cancers. In this trial, a replication-deficient recombinant p53-wild type carrying adenovirus was administered intraperitoneally in combination with systemic platinum-based chemotherapy for front-line treatment of minimal residual disease after primary surgical cytoreduction. Although there are a numGene Therapy ber of studies dealing with the expression of CAR in established ovarian cancer cell lines, only few data exist on the distribution of CAR in ovarian cancer tissue. In the only investigation we know, immunohistochemical determinations were performed on formalin-fixed, paraffin-embedded tissue and the staining pattern was reported to be predominantly minimally reactive. 17 In a pilot approach we compared our method performed either on cryosections or on paraffin-embedded sections and found that immunoreactivity was lowered by 65% in paraffin-embedded specimens (data not shown). Thus, in our opinion, formalin-fixed, paraffin-embedded tissue does not represent the appropriate material for investigating CAR expression by immunohistochemistry. With regard to the expression and distribution of ␣v␤3 and ␣v␤5 integrins in ovarian cancer, little information is actually available. 15, 35 The present investigations reveal that an absolute absence of CAR seems to be rare in ovarian cancer and occurred only in one undifferentiated carcinoma in our set of 37 investigated specimens. However, 61% of the studied specimens showed a focal pattern of heterogeneity with regard to negative and positive intratumoral regions, namely one found to be the most pronounced in grade 3 tumors or those classified as undifferentiated. Such distribution differences in the expression of CAR might possibly account for a growth selection of CARnegative cells, which during treatment remain unaffected by adenovirus-mediated gene transfer and could be one possible explanation for the restrictions encountered in the in vivo gene therapeutic approaches.
Our findings of highest demonstrable RmcB reactivity in well-differentiated tumors appear to corroborate recent reports, which showed that the lack of CAR expression is associated with high tumorigenicity in cancer cells and that, in addition to its function as a virus receptor, CAR exhibits cell-adhesive activity generally known to correspond to high differentiation of tumor cells.
14 The absence of CAR expression shown here in the stromal component of ovarian carcinomas is in accordance with the findings of others, indicating that fibroblasts are CAR-deficient. 21, 36 However, the few existing data on immunohistochemical determination of CAR make it difficult to speculate on the sensitivity of this method at the cellular level, so that we ultimately cannot rule out the possibility that cells considered negative by immunohistochemical means may indeed express a small number of CAR molecules, insufficient for immunohistochemical detection, but with some biological activity. In this context it is worth mentioning that a close relationship between the cellular level of CAR expression and the adenovirus-based transduction rate has been established in a number of investigations, 24, 25 so that at best the lack of CAR immunostaining could reflect minor susceptibility for adenoviral cell entry.
These concerns are also valid for immunohistochemical determination of the integrins ␣v␤3 and ␣v␤5. The rate of positivity for these molecules promoting adenoviral internalization was about 65% for both classes and thus lower than that obtained for CAR. In addition, positive samples exhibited a high incidence of focal distributional heterogeneity of integrin ␣v␤3 (48%) and ␣v␤5 (58%) expression. Given the recent observations indicating a key role in adenoviral transduction for the integrin ␤3 subunit in ovarian cancer cell lines, 26 our finding that the ␣v␤3 class of integrins was totally absent in undifferentiated ovarian cancers merits special attention. The presence of ␣v␤5 and the absence of ␣v␤3 integrins in the stromal tumor component, as well as the pronounced immunostaining for both classes in the endothelial cells of tumor vessels are in agreement with the reports of other authors. [37] [38] [39] If for each individual tumor the immunohistochemical data of the three investigated cell surface molecules are taken together, 60% of the investigated ovarian cancers in our opinion should not be regarded as eligible for adenovirus-based treatments. In these cases either a complete lack of CAR, ␣v␤3 and/or ␣v␤5 integrins or a pronounced focal heterogeneity in antigen expression was determinative for non-eligibility. Three specimens (8%) with demonstrated focal small negative cell clusters interspersing an otherwise positive tumor were considered to have intermediate suitability for adenoviral therapies with reference to the possibility that small negative clusters could theoretically be affected by an unspecific immunological bystander effect induced by adenoviral infections of surrounding cells. 40 Only 32% of the tumors analyzed, which are predominately grade 1 carcinomas, can be expected to exhibit high susceptibility for adenovirus-directed targeting, thus making them suitable candidates for such an approach.
Nonetheless, we are aware that adenovirus infectability of an individual tumor and moreover of each of its composing cells can ultimately be proved by transfection assays using living virus particles, but considering the actual understanding of adenoviral cell entry, the molecules studied herein may serve as reliable surrogate parameters for predicting adenoviral infectivity.
In conclusion, our investigations suggest that highgrade ovarian cancers and especially those classified as undifferentiated may be poor targets for adenoviral vectors and should be considered a critical subset of carcinomas for adenovirus-based therapeutic strategies. The results of our immunohistochemical evaluations tempt us to speculate that intratumoral heterogenicity in the expression of the molecules decisively involved in adenoviral cell entry, as found predominately in undifferentiated and high-grade serous and mucinous ovarian cancers, could be the origin of an unfavorable growth selection of negative cell clones compromising the efficiency of adenovirus-based therapies. Such discrepancies in infectability in the same tumor may argue in favor of multi-vector strategies in future gene therapeutic concepts. Furthermore, before eligibility for adenovirusbased treatment is certified in coming therapy protocols, it is recommended to determine tissue distribution and the degree of expression of the major determinants for cellular adenovirus uptake in order to evaluate the susceptibility of the malignant tissues to be targeted by adenoviral vectors.
Materials and methods
Specimens
Ovarian carcinoma samples were obtained from 37 females between 35 and 78 years of age (median age, 59 years), who underwent primary debulking surgery for ovarian cancer at the Department of Obstetrics and Gynecology of Innsbruck University Hospital between January 2000 and March 2001. Histopathologic diagnosis was performed by the Gynecopathology Unit of our hospital. For the purpose of the present study one single histopathologist (EM-H) critically reviewed subtype diagnosis and tumor grade using paraffin-embedded, hematoxylinand eosin-stained sections. Patients were staged according to the 1986 revised staging system of the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO). Excluded from the study were specimens from patients who had previously received systemic chemotherapy (including neoadjuvant chemotherapy for ovarian cancer before surgery) or radiation therapy. Samples from subjects suffering from other conditions such as acute inflammatory disease and autoimmune disorders, which could potentially affect the expression of cellular surface molecules, were also rejected for investigation. None of the patients had a history of abdominal surgery during the preceding year.
Immediately after surgery, representative samples of the carcinomas were isolated by the gynecopathologist and divided into two equal parts. One was used for cryostat sections (4 m), which were stored at Ϫ80°C until immunohistochemical investigation. The other part was immediately fixed in 4% buffered formalin, pH 7.0, and routinely processed for paraffin embedding.
Immunohistochemistry
Cryosections were fixed with acetone for 5 min at Ϫ20°C and after washing with tris-buffered saline (pH 7.6) were incubated for 1 h with the respective primary monoclonal antibody RcmB, 18 anti-␣v␤3 LM609 or anti-␣v␤5 P1F6, both purchased from Chemicon International (Temecula, CA, USA). Primary antibodies were diluted with RPMI solution to a concentration of 1:800. RPMI solution consisted of 5 ml RPMI-1640 (PAA Laboratories, Linz, Austria), 45 ml distilled water, 5 ml bovine serum (Sigma, St Louis, MO, USA) and 0.05 g sodium acid (pH 7.4). Thereafter specimens were incubated for 30 min with the secondary rabbit anti-mouse antibody (Dako, Glostrup, Denmark) diluted 1:30 with the above-mentioned RPMI solution supplemented with 15% human serum. For antigen staining, the alkaline phosphatase and mouse monoclonal anti-alkaline phosphatase (APAAP) system (Dako) was applied according to the manufactureŕs instructions. For exposure chromogenic substrate consisting of 49 ml tris-buffered saline (pH 7.6) containing 0.012 g levamisol (Sigma), 0.01g naphtol AS-Mx phosphate (Sigma), 1 ml N,N-dimethylformamide (Sigma) and 0.05g fast red (Sigma) was applied for 30 min. Counterstaining was performed with hematoxylin, and finally, slides were mounted with Glycergel (Dako).
Results were evaluated using a Histo-Score (HScore) obtained by summing the proportion (in %) of cells staining at each intensity (Pi) multiplied by the intensity of staining (i: 0-3), to give the following formula: HScore = ⌺ Pi (i).
The HScore was determined by two independent observers. Differences >10% occurred in four of 37 (10.8%) cases and were resolved by consensus. Specimens exhibiting a proportion Ն10% of staining cells were considered positive. Special attention was attributed to the intratumoral distribution of staining cells. Two distribution patterns were distinguished: (1) a randomly scattered cell positivity; and (2) a focal staining pattern characterized by either small negative tumor cell clusters (+) or larger negative tumor areas (++), interspersing an otherwise positive tumor or positive tumor cell clusters interposed between large negative tumor regions (+++).
In negative controls, either the specific antibody was replaced with normal mouse serum or isotype-matched control mouse antibodies or the secondary rabbit antimouse immunoglobulin G was replaced with normal rabbit immunoglobulin-G. All negative controls exhibited no staining. For assessment of both integrin classes, sections of normal mammary glands available in our tissue bank were used as positive controls. The established ovarian cancer cell line OVCAR-3 exhibiting high CAR expression as demonstrated by RT-PCR 22 served as the positive control for immunohistochemical determination of CAR.
Statistical analysis
Statistical analysis was performed using the BMDP software package. Data were analyzed using non-parametric tests, and results expressed as median values with the first (Q 1 ) and third quartile (Q 3 ). Differences in median values were evaluated using the Mann-Whitney U test. Correlations were calculated using the Spearman rank correlation coefficient (r s ). P values Ͻ0.05 were considered significant.
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